CLOS
CODX

Compagnie Lombard Odier SCmA’s Co-Diagnostics CODX Stock Holding History

Compagnie Lombard Odier SCmA’s Portfolio CODX Stock Details CODX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-67
Closed -$19K – 688
2021
Q3 		$19K Hold
67
– – ﹤0.01% 566
2021
Q2 		$17K Hold
67
– – ﹤0.01% 564
2021
Q1 		$19K Buy
+67
New +$26.7K ﹤0.01% 580

Other funds holding CODX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PPA
Parametric Portfolio Associates Seattle, Washington $190B AUM 18.52% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
ARC
Advisor Resource Council Dallas, Texas $355M AUM 30.05% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Compagnie Lombard Odier SCmA's CODX Position: Q4 2021 in Review

Compagnie Lombard Odier SCmA sold out of Co-Diagnostics (CODX) in Q4 2021, closing a stake of 67 shares — an estimated $19K sold.

Compagnie Lombard Odier SCmA first reported a position in CODX in Q1 2021 and held it in 3 quarters. The position peaked at $19K in Q3 2021. 77 funds tracked by Wall St. Rank hold CODX as of Q4 2021.

  • Compagnie Lombard Odier SCmA reported no remaining Co-Diagnostics position as of Q4 2021 after selling out during the quarter.
  • Compagnie Lombard Odier SCmA sold 67 Co-Diagnostics shares in Q4 2021, an estimated $19K.
  • Compagnie Lombard Odier SCmA first reported a position in Co-Diagnostics in Q1 2021 and held it in 3 quarters.
  • Compagnie Lombard Odier SCmA's Co-Diagnostics position peaked at $19K in Q3 2021.
  • 77 funds tracked by Wall St. Rank held Co-Diagnostics as of Q4 2021.

Based on Compagnie Lombard Odier SCmA's 13F filing for Q4 2021, filed 9 Feb 2022.